Nicanartine improves in vitro resistance of lipoproteins to oxidation

Pharmaceutical Research

Volumn 13, Issue 3, 1996, Pages 457-461

  Dailly, Eric ^a   Urien, Saïk ^a   Wülfroth, Petra ^b   Tillement, Jean Paul ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Lipoprotein; Nicanartine; Oxidation; Plasma binding

Indexed keywords

ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICANARTINE; VERY LOW DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG PROTEIN BINDING; ERYTHROCYTE; HUMAN; HUMAN CELL; OXIDATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL;

ADULT; ANTIOXIDANTS; BLOOD PROTEINS; ERYTHROCYTES; HUMANS; LIPOPROTEINS; OXIDATION-REDUCTION; PROTEIN BINDING; PYRIDINES;

EID: 0029966465     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016013130445     Document Type: Article

References (14)

1. T. Henriksen, E. M. Mahoney, and D. Steinberg. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetylated low density lipoproteins. Proc. Nat. Acad. Sci. USA. 78:6499-6503 (1981).
2. U. P. Steinbrecher, S. Parthasarathy, D. S. Leake, J. L. Witztum, and D. Steinberg. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Nat. Acad. Sci. USA. 81:3883-3887 (1984).
3. J. T. Salonen, S. Yla-Herttuala, R. Yamamoto, and al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339:883-887 (1992).
4. M. K. Cathcart, D. W. Morel, G. M. Chisolm. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J. Leukocyte Biol. 38:341-350 (1985).
5. M. T. Quinn, S. Parthasarathy, L. G. Fong, D. Steinberg. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Nat. Acad. Sci. USA. 84:2995-2998 (1987).
6. P. Wülfroth, A. Bartmann, C. C. Hopstock, and J. E. Reichel. The new antioxidant Mrz 3/124 improves lipid status and prevents oxidative injury to endothelial cells and macrophages. Bulletin of molecular biology in medicine (in press).
7. R. J. Havel, H. A. Eder, and J. M. Bragdon. The distribution and chemical composition of ultracentrifugally separated lipoprotein in human serum. J. Clin. Invest. 34:1345-1354 (1955).
8. H. Esterbauer, G. Striegl, H. Puhl, and M. Rotheneder. Continuous monitoring of in vitro oxidation of human low-density lipoprotein. Free Radic. Res. Commun. 6:67-75 (1989).
9. S. Urien, G. Bastian, C. Lucas, J. P. Bizzari, and J. P. Tillement. Binding of a new vinca alkaloid derivative, S 12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partioning technique. Investigational New Drugs 10:263-268 (1992).
10. S. Urien, P. Claudepierre, J. Meyer, R. Brandt, J. P. Tillement. Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes. Biochem. Pharmacol. 44:1891-1893 (1992).
11. S. Urien, P. Riant, A. Renouard, A. Coulomb, I. Rocher, J. P. Tillement. Binding of indapamide to serum proteins and erythrocytes. Biochem Pharmacol. 37:2963-2966 (1988).
12. L. R. Mc Lean, K. A. Hagaman. Effect of Probucol on the physical properties of low-density lipoproteins oxidized by copper. Biochemistry. 28:321-327 (1989).
13. E. Lupo, R. Locher, B. Weisser, and W. Vetter. In vitro antioxidant activity of calcium antagonists against low-density lipoprotein oxidation compared with alphatocopherol. Biochem. and Biophys. Res. Commun. 203:1803-1808 (1994).
14. V. W. Bowry, K. K. Stanley, and R. Stocker. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Nat. Acad. Sci. USA. 89:10316-10320 (1992).